trending Market Intelligence /marketintelligence/en/news-insights/trending/co4ftzpdGATP6g2-taAaTA2 content esgSubNav
In This List

US FDA grants priority review for Tesaro's cancer drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA grants priority review for Tesaro's cancer drug

The U.S. FDA granted a priority review to Tesaro Inc.'s new drug application for niraparib, a poly ADP-ribose polymerase inhibitor.

Niraparib is being evaluated as a potential new treatment option for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer following response to platinum-based chemotherapy.

The application for niraparib is supported by a phase 3 study that showed that niraparib treatment significantly prolonged progression-free survival compared to placebo.

The FDA set a target action date under the Prescription Drug User Fee Act of June 30, 2017, and is not planning to hold an advisory committee meeting to discuss the application.

An expanded access program for niraparib in the U.S. is planned to open in January 2017.